EUVIMEDEUVIMED entdecken
Crossref

Outcomes of relapsed/refractory extracranial germ cell tumors treated on conventional salvage chemotherapy without stem cell rescue: Experience from a tertiary cancer center

Subramaniam Ramanathan, Maya Prasad iD, Tushar Vora, Cheriyalinkal Parambil Badira iD, Seema Kembhavi, Mukta Ramadwar, Nehal Khanna, Siddhartha Laskar iD, Mary Ann Muckaden, Sajid Qureshi iD, Shripad Banavali, Girish Chinnaswamy

Pediatric Blood & Cancer · 2023

DOI: 10.1002/pbc.30179 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2023. Verfasst von Subramaniam Ramanathan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatric Oncology, Great North Children's Hospital, Royal Victoria Infirmary, Newcastle upon Tyne, Tyne and Wear, UK. Hauptthemen laut MEDLINE: Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aims Data on the outcome and prognostic indicators in extracranial relapsed/refractory germ cell tumors (rel/ref‐GCTs) in children are limited to a few studies. This study looks at remission rates and outcomes of rel/ref‐GCTs treated with conventional salvage chemotherapy (SC) regimens without stem cell rescue at a single center in the developing world.

Methods

Patients treated at our center from January 2009 to December 2018 were included. Risk at primary presentation was stratified as all completely excised teratomas and stage I gonadal tumors being low risk (LR); stage IV ovarian, stage III–IV extragonadal GCTs as high risk (HR), and the remaining as intermediate risk (IR). SC regimens were: vinblastine–ifosfamide–cisplatin/carboplatin or paclitaxel–ifosfamide–cisplatin/carboplatin, or cisplatin/carboplatin–etoposide–bleomycin. Local therapy was either surgery and/or radiotherapy.

Results

The analyzable cohort comprised 50 patients (44 = rel‐GCTs; 6 = ref‐GCTs) with a median age of 3.8 years and male:female ratio of 1.27:1. Primary location was ovary in 16 (32%), testicular in 10 (20%), and extragonadal in the rest (48%). Local, metastatic, and combined progression was noted in 28 (56%), 14 (28%), and eight (16%) patients, respectively, at a median time of 8.5 months. At a median follow‐up of 60 months, the 5‐year event‐free survival (EFS) and overall survival (OS) of the entire cohort ( n = 50) were 42.4% and 50.0%, respectively. In patients previously exposed to platinum analogs ( n = 38), 5‐year‐EFS and OS were 27.7% and 31.7%, respectively. Local relapses did better when compared to metastatic and combined relapses (5‐year EFS: 64% vs. 23% vs. 0%; p = .009). LR and IR tumors did better compared to HR (5‐year EFS: 81.5% vs. 49.3% vs. 6.5%; p = .002). Patients with normalization of tumor markers after two cycles had a superior EFS (57.6% vs. 0%; p < .001). Relapsed tumors fared better than primary refractory GCTs (5‐year EFS: 48.6% vs. 0%; p < .001).

Conclusions

Primary refractory GCTs, extragonadal rel‐GCTs, and rel/ref‐GCTs with a poor biochemical response did poorly with conventional SC and need alternative treatment strategies. The rel/ref‐testicular GCTs had the best chance of salvage despite a second recurrence (5‐year EFS and OS: 28.60% and 42.90%, respectively).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasms, Germ Cell and EmbryonalTesticular NeoplasmsChildHumansMaleFemaleChild, PreschoolCarboplatinCisplatinIfosfamideEtoposideNeoplasm Recurrence, LocalAntineoplastic Combined Chemotherapy ProtocolsSalvage Therapy

Stichwörter der Autor:innen

childhood cancerdeveloping countrygerm cell tumorsrare tumorsrefractory GCTsrelapsed GCTssalvage chemotherapy

Substanzen

CarboplatinCisplatinIfosfamideEtoposide

Autor:innen und Institutionen

  • Department of Paediatric Oncology, Great North Children's Hospital, Royal Victoria Infirmary, Newcastle upon Tyne, Tyne and Wear, UK.
  • Department of Paediatric Oncology, Tata Memorial hospital, Mumbai, Maharashtra, India.
  • Homi Bhabha National Institute, Mumbai, Maharashtra, India.
  • Department of Paediatric Oncology, SickKids Hospital, Toronto, Ontario, Canada.
  • Department of Radiology, Mackay Hospital and Health Services, Mackay, Queensland, Australia.
  • Department of Pathology, Tata Memorial Hospital, Mumbai, Maharashtra, India.

ORCID-Profile: Maya Prasad, Cheriyalinkal Parambil Badira, Siddhartha Laskar, Sajid Qureshi

Zitieren

APA

Ramanathan, S., Prasad, M., Vora, T., Badira, C. P., Kembhavi, S., Ramadwar, M., Khanna, N., Laskar, S., Muckaden, M. A., Qureshi, S., Banavali, S., & Chinnaswamy, G. (2023). Outcomes of relapsed/refractory extracranial germ cell tumors treated on conventional salvage chemotherapy without stem cell rescue: Experience from a tertiary cancer center. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30179

Vancouver

Ramanathan S, Prasad M, Vora T, Badira CP, Kembhavi S, Ramadwar M, et al. Outcomes of relapsed/refractory extracranial germ cell tumors treated on conventional salvage chemotherapy without stem cell rescue: Experience from a tertiary cancer center. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30179

BibTeX
@article{Ramanathan2023,
  author = {Ramanathan, Subramaniam and Prasad, Maya and Vora, Tushar and Badira, Cheriyalinkal Parambil and Kembhavi, Seema and Ramadwar, Mukta and Khanna, Nehal and Laskar, Siddhartha and Muckaden, Mary Ann and Qureshi, Sajid and Banavali, Shripad and Chinnaswamy, Girish},
  title = {Outcomes of relapsed/refractory extracranial germ cell tumors treated on conventional salvage chemotherapy without stem cell rescue: Experience from a tertiary cancer center},
  journal = {Pediatric Blood & Cancer},
  year = {2023},
  doi = {10.1002/pbc.30179}
}
Kostenlos starten →